According to Pharmatimes.com, “The UK is paying less for new cancer drugs than most other countries in Europe, a new report has found. The study in The Lancet Oncology also reveals that the prices of such drugs vary widely – from 28 percent to 388 percent – between high-income European countries, Australia, and New Zealand.” For more information, please visit: http://www.pharmatimes.com/Article/15-12-04/UK_paying_less_for_cancer_drugs_than_other_EU_countries.aspx